In a major milestone for the Sultanate’s healthcare landscape, Omani innovator Zaher bin Salem bin Awad Al Alawi has successfully engineered a high-tech biotechnology platform dedicated to treating chronic wounds. Developed under the banner of the Sustainable Algae Company (Tuhlab Al Mustadama), this project specifically addresses the challenges of diabetic ulcers and persistent injuries through advanced bio-delivery systems. This innovation marks a shift within Oman toward precision medicine, moving beyond basic treatments to a sophisticated ecosystem capable of meeting the complex needs of patients across the region.
The inspiration for this breakthrough was deeply personal, rooted in Al Alawi’s observation of the difficulties faced by his mother during her recovery from diabetic-related wounds. His academic path began at Sultan Qaboos University, where he initially researched the healing properties of natural compounds, before advancing his expertise in the UK and returning to Oman to finalize his doctoral work. By integrating biomedical engineering tools like hydrogels, the platform ensures that therapeutic agents are delivered with pinpoint accuracy to the affected tissue, significantly improving recovery rates for Omani patients.
This Omani-led initiative is set for international exposure as Al Alawi prepares to represent the Sultanate at the International Invention, Innovation and Technology Exhibition (ITEX 2026) in Malaysia this May. Closer to home, the project has already undergone rigorous review by experts at the Ministry of Health to ensure full alignment with Omani clinical protocols and safety standards. This synergy between local talent and national health authorities underscores Oman's commitment to fostering a digital and scientific transformation that directly improves the quality of life for its citizens.
With the final development phases currently underway, the commercial launch of the first product is anticipated for the fourth quarter of 2026. By securing global partnerships and focusing on scalable biotech solutions, Al Alawi is positioning his work as a premier Omani contribution to the global life sciences market. This achievement provides a vital new tool for managing diabetes complications in the Sultanate and cements Oman’s reputation as a growing center for world-class scientific research and medical innovation.
